Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Kiniksa Pharmaceuticals International's Other Non Operating Income rose 2763.53% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year increase of 1001.79%. This contributed to the annual value of $9.5 million for FY2024, which is 1076.78% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Other Non Operating Income is $3.1 million, which was up 2763.53% from $2.7 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Other Non Operating Income's 5-year high stood at $3.1 million during Q3 2025, with a 5-year trough of $34000.0 in Q1 2022.
  • For the 4-year period, Kiniksa Pharmaceuticals International's Other Non Operating Income averaged around $1.8 million, with its median value being $2.3 million (2025).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 528823.53% in 2023, then tumbled by 206.84% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Other Non Operating Income (Quarter) stood at $794000.0 in 2022, then soared by 198.36% to $2.4 million in 2023, then fell by 2.07% to $2.3 million in 2024, then surged by 35.17% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $2.7 million for Q2 2025, and $2.3 million during Q1 2025.